Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia

Exclusion Criteria

• •Age \< 18 or legal age of adulthood, whichever was greater
• •LDL-C \< 100 mg/dL (\< 2.59 mmol/L) or \> 190 mg/dL (\> 4.9 mmol/L)
• •Fasting serum triglycerides (TG) \> 400 mg/dL (\> 4.52 mmol/L)
• •Known history of homozygous or heterozygous familial hypercholesterolemia
• •The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.